Abstract:Carla Bolano-Diaz, 1 Jordi Diaz-Manera 1– 3 1 The John Walton Muscular Dystrophy Research Center, Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK; 2 Laboratori de Malalties Neuromusculars, Insitut de Recerca de l'Hospital de la Santa Creu i Sant Pau de Barcelona, Barcelona, Spain; 3 Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain Correspondence: Jordi Diaz-Manera, The John Walton Muscular Dystrophy Research Center, Center for Life, Central Parkway, Newcastle Upon Tyne, NE13BZ, UK, Email Pompe disease is a genetic disorder produced by mutations in the GAA gene leading to absence or reduced expression of acid alpha-glucosidase, an enzyme that metabolizes the breakdown of glycogen into glucose. There are two main phenotypes, the infantile consisting of early onset severe weakness and cardiomyopathy, and the adult which is characterized by slowly progressive skeletal and respiratory muscle weakness. Enzymatic replacement therapy (ERT) has been available for Pompe disease for more than 15 years. Although the treatment has improved many aspects of the disease, such as prolonged survival through improved cardiomyopathy and acquisition of motor milestones in infants and slower progression rate in adults, ERT is far from being a cure as both infantile and adult patients continue to progress. This fact has prompted the development of improved or new enzymes and other treatments such as gene therapy or substrate reduction strategies. Here, we review the data obtained from randomized clinical trials but also from open-label studies published so far that have assessed the advantages and limitations of this therapy. Moreover, we also review the new therapeutic strategies that are under development and provide our opinion on which are the unmet needs for patients with this disease. Keywords: glycogen storage disease type II, Pompe disease, enzyme replacement therapy, recombinant human acid alpha-glucosidase, genetic therapy, clinical trials Pompe disease is a genetic glycogen storage disorder with an autosomal recessive pattern of inheritance. 1,2 The epidemiology of the disease is not clearly established although is suggested to be of almost 1:40,000 individuals. 3 There is however demographic variability, from countries with just a few cases described to others with a higher prevalence. 4–6 It is produced by mutations in the GAA gene localized to chromosome 17 which codifies for the enzyme acid alpha-glucosidase (AAG). 7 AAG is responsible for the breakdown of glycogen into glucose inside the lysosomes of the cells. A deficient enzyme activity leads to the accumulation of glycogen within cells of many tissues. However, patients' symptoms are mainly related to the dysfunction of skeletal, cardiac and smooth muscle and neurons, which are tissues with a high glucose demand. 2 Two main clinical disease phenotypes have traditionally been described: the infantile (classic and non-classic) and the late onset Pompe phenotypes. 2 Classic infantile onset Pompe disease (IOPD) typically presents early after birth with severe generalized muscle weakness, hypotonia, respiratory insufficiency and hypertrophic cardiomyopathy that, if left untreated, leads to death within the first year of life. IOPD patients can also show other associated symptoms such as hepatomegaly, feeding difficulties and macroglossia. 2,8 These patients have zero or very reduced AAG protein expression, which can be detected using Western blot (WB) analysis, a technique commonly described as cross-reactive immunologic material (CRIM) in the scientific papers. Those patients who have some residual enzyme activity are labeled as CRIM positive while those with no residual activity are labeled CRIM negative. 9 The term non-classic infantile onset Pompe disease is generally used to describe patients who have early onset of muscle weakness during the first two years of life with or without respiratory muscle dysfunction, but who do not develop cardiac involvement. 2 These patients can present very early in life with severe muscle weakness, or a bit later with a delay in the acquisition of motor milestones. As these patients grow, they develop other complications such as scoliosis, dysphagia, hepatomegaly, irritable bowel disease and joint contractures. 10 The term juvenile onset Pompe disease is used to describe patients who start presenting symptoms after 2 years of age, during childhood or adolescence. 10 Nowadays, this group of patients is usually included within the most severe end of patients with late onset Pompe disease (LOPD) and the term juvenile onset is being progressively abandoned. The cl -Abstract Truncated-

Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database

Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis

Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa

Real‐life effectiveness 1 year after switching to avalglucosidase alfa in late‐onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease

Evaluating avalglucosidase alfa for the management of late-onset Pompe disease

Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial

First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data

Pompe disease: Unmet needs and emerging therapies

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database

Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry

Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of Enzyme Replacement Therapy in Pompe disease

Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management

Response to Comments on "Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice"

Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review

Significance of early diagnosis and treatment of adult late-onset Pompe disease on the effectiveness of enzyme replacement therapy in improving muscle strength and respiratory function: a case report

Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease